Abstract
Introduction: The coronavirus disease 2019 (COVID-19) pandemic is affecting populations worldwide. Remdesivir is an anti-retroviral agent, with a broad spectrum of usage. Remdesivir usage against COVID-19 had been studied both in vitro and in vivo but is still considered a new treatment for COVID-19 and is not available in all countries. The aim of our study was to report several cases of the use of remdesivir in Sudanese patients and report the adverse events related to the course of treatment. Methods: A case series study was conducted in Imperial Hospital, Khartoum, Sudan reporting two cases who received remdesivir for treating COVID-19 besides other treatments such as steroids and supportive therapy in December 2020. Cases were males aged over 65 years. Cases presentation: Both patients were severe cases of COVID-19 admitted to the intensive care unit (ICU), who received remdesivir for treating COVID-19 infection. Several side effects were reported: the first case had increased liver enzymes and then unexpectedly died from severe resistant hypotension; and hypoalbuminemia was noticed in the second case. Conclusions: Remdesivir use among patients in Sudan must be studied extensively in order to determine the unexpected fatal event and assess the association of this event to remdesivir use, as well as to report the frequency of the side effects.
Highlights
The coronavirus disease 2019 (COVID-19) pandemic is affecting populations worldwide
The aim of our study was to report the use of remdesivir among two cases in Sudan and report the adverse events related to the course of treatment
Remdesivir doses administered for our patients were a 200 mg intravenously loading dose followed by 100 mg daily dose, which is the recommended dosage.[9,15]
Summary
The coronavirus disease 2019 (COVID-19) pandemic is affecting populations worldwide. Remdesivir is an anti-retroviral agent, with a broad spectrum of usage. The coronavirus disease 2019 (COVID-19) pandemic is affecting people worldwide with all populations susceptible to getting infected; especially health care personnel and elderly populations.[1] Concomitant comorbid conditions, such as diabetes mellitus (DM), are related to increased severity of COVID-19 symptoms.[1,2] Remdesivir is an anti-retroviral agent, with a broad spectrum of activity It is a prodrug, which was first developed to be used for the treatment of Ebola.[3] Recently, it was proposed to treat COVID-19 infection.[4,5] The use of remdesivir against COVID-19 had been studied both in vitro and in vivo, but still considered new for COVID-19 treatment and not available in all countries.[6,7] some remdesivir trials have not had enough power,[8] one large scale clinical trial has been done, in which, there was no statistically significant difference in the improvement time with the use of remdesivir (hazard ratio 1.23 [95% confidence interval (CI) 0.87–1.75]. The aim of our study was to report the use of remdesivir among two cases in Sudan and report the adverse events related to the course of treatment
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
